ERβ in breast cancer—onlooker, passive player, or active protector?
EM Fox, RJ Davis, MA Shupnik - Steroids, 2008 - Elsevier
The role of estrogen exposure in breast cancer risk is well-documented, and both estrogen
synthesis and actions through the estrogen receptor (ER) have been targeted by therapies
to control hormone-dependent breast cancer. The discovery of a second ER form and its
therapeutic implications sparked great interest. Both the original ERα and the more recently
identified ERβ subtypes bind and respond similarly to many physiological and
pharmacological ligands. However, differences in phytoestrogen binding have been noted …
synthesis and actions through the estrogen receptor (ER) have been targeted by therapies
to control hormone-dependent breast cancer. The discovery of a second ER form and its
therapeutic implications sparked great interest. Both the original ERα and the more recently
identified ERβ subtypes bind and respond similarly to many physiological and
pharmacological ligands. However, differences in phytoestrogen binding have been noted …
